Equivalent findings were recently described in hepatocellular carcinoma patient-derived T-cells, with the CD137HI CD8+ subset displaying a superior antitumor reactivity and expressing, amongst others, higher IFN-γ levels [49]. This evidence concerns the gene CD8A and hepatocellular carcinoma.